257 related articles for article (PubMed ID: 36825043)
1. Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience.
Castillo-Torres SA; Lees AJ; Merello M
Mov Disord Clin Pract; 2023 Feb; 10(2):190-208. PubMed ID: 36825043
[TBL] [Abstract][Full Text] [Related]
2. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
Corboy DL; Wagner ML; Sage JI
Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
[TBL] [Abstract][Full Text] [Related]
5. [Apomorphine in off state--clinical experience].
Rudzińska M; Szczudlik A
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
7. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
Carbone F; Djamshidian A; Seppi K; Poewe W
CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine in patients with Parkinson's disease.
Muguet D; Broussolle E; Chazot G
Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
[TBL] [Abstract][Full Text] [Related]
9. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
10. [Apomorphine in treatment of Parkinson's disease with fluctuations].
Zaleska B; Domzał T
Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
[TBL] [Abstract][Full Text] [Related]
11. Dopamine agonists in Parkinson's disease: a look at apomorphine.
Lees AJ
Fundam Clin Pharmacol; 1993; 7(3-4):121-8. PubMed ID: 8500783
[TBL] [Abstract][Full Text] [Related]
12. Apomorphine hydrochloride for the treatment of Parkinson's disease.
Unti E; Ceravolo R; Bonuccelli U
Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
[TBL] [Abstract][Full Text] [Related]
13. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
Koller W; Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
[TBL] [Abstract][Full Text] [Related]
14. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
Caughman CY; Factor S
Expert Rev Neurother; 2021 Feb; 21(2):169-177. PubMed ID: 33227223
[No Abstract] [Full Text] [Related]
15. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
Deffond D; Durif F; Tournilhac M
J Neurol Neurosurg Psychiatry; 1993 Jan; 56(1):101-3. PubMed ID: 8429309
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
Pietz K; Hagell P; Odin P
J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):709-16. PubMed ID: 9810943
[TBL] [Abstract][Full Text] [Related]
17. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary?
Hauser RA; Ondo WG; Zhang Y; Bowling A; Navia B; Pappert E; Isaacson SH;
J Parkinsons Dis; 2023; 13(3):403-414. PubMed ID: 36970914
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine: an underutilized therapy for Parkinson's disease.
Poewe W; Wenning GK
Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
[TBL] [Abstract][Full Text] [Related]
20. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
